Lucid Diagnostics Inc

Lucid Diagnostics maintains a capital structure characterized by zero debt, with a debt-to-equity ratio of 0.0. The company holds total assets of $40.4 million against total liabilities of $29.5 million, resulting in total equity of $10.9 million. Despite the absence of debt, the firm faces significant liquidity pressures, evidenced by an operating cash flow of -$46.5 million. The market capitalization stands at approximately $130 million, implying a price-to-book ratio of 11.87, which suggests the market is pricing in substantial future growth potential despite current negative book value returns.

Profitability metrics indicate severe operational losses, with net income at -$58.0 million and operating income at -$49.6 million for the latest period. Return on equity is -4.12% and return on assets is -1.11%, reflecting the company's pre-profitability stage. Without cohort median data for direct comparison, these figures are evaluated against the industry norm for early-stage health care equipment firms, where high R&D and sales expenses typically depress near-term margins. The revenue base of $4.7 million is insufficient to cover the substantial operating burn, highlighting the company's reliance on external capital to sustain operations.

Lucid Diagnostics Inc (LUCD.O) has undergone a significant internal revision of its analytical profile, with the AI-driven narrative, business summary, and conclusion all marked as modified with low similarity scores to prior versions. This structural update, sourced from the ha_light_thesis, indicates a fundamental shift in how the company's operational and strategic position is being characterized, even in the absence of new external market events. The revision process involved a substantial reduction in key takeaways, with eight items removed and none added, suggesting a streamlining or consolidation of the company's primary value drivers. This change in the analytical framework implies that previous distinct factors may have been merged or deemed less critical, altering the lens through which the company's performance is evaluated. Despite these internal analytical shifts, there is a notable absence of external market activity or news flow. The cross-source signals show zero dispatches and null sentiment readings for every day from June 24, 2026, through July 14, 2026, indicating a period of quiet market engagement. This lack of external noise contrasts with the internal data updates, highlighting that the changes are driven by analytical re-evaluation rather than new corporate developments. The company's fundamental structure remains static, with no reported changes in officer count, analyst coverage, or index membership. With 21 top holders identified but no new analyst ratings or index inclusions, the current landscape for Lucid Diagnostics is defined by this internal recalibration of its business narrative amidst a backdrop of market silence. Investors should note that the revised analytical conclusions reflect a re-weighting of existing information rather than a response to new financial or operational data.

Revenue grew 75.2% CAGR over four years, indicating strong top-line expansion momentum for the diagnostic company.

Analysts project 324.7% upside to a mean price target of $3.95, signaling significant expected valuation recovery.

The company maintains a low dilution risk profile, suggesting limited immediate threat to existing shareholder equity value.

Cash conversion ratio of 1.03 exceeds the cohort median of 0.84, demonstrating superior operational cash efficiency.

Current ratio of 1.31 indicates adequate short-term liquidity to cover immediate liabilities despite ongoing operational losses.

The company carries a high credit risk flag, indicating significant potential for default or financial distress.

Operating margin of -9.8% places the firm in the bottom quartile of its 335-company medical equipment cohort.

Debt-to-equity ratio of 2.70 falls into the high leverage band, increasing financial vulnerability during downturns.

Revenue $1.3M, +51,7% YoY; Operating income +3,0% YoY.

• ▍Revenue $1.3M, +51,7% YoY
• ▍Operating income +3,0% YoY
• ▍Net income +48,3% YoY
• ▍Free cash flow +34,2% YoY
• ▍Net margin -1107.4%

Revenue $1.5M, +25,6% YoY; Operating income +14,7% YoY.

• ▍Revenue $1.5M, +25,6% YoY
• ▍Operating income +14,7% YoY
• ▍Net income −40,9% YoY
• ▍Free cash flow −39,1% YoY
• ▍Net margin -1081.5%

Revenue $1.2M, +3,3% YoY; Operating income −5,8% YoY.

• ▍Revenue $1.2M, +3,3% YoY
• ▍Operating income −5,8% YoY
• ▍Net income +16,0% YoY
• ▍Free cash flow +18,4% YoY
• ▍Net margin -858.5%

Revenue $1.2M, +19,2% YoY; Operating income +2,7% YoY.

• ▍Revenue $1.2M, +19,2% YoY
• ▍Operating income +2,7% YoY
• ▍Net income +59,7% YoY
• ▍Free cash flow +28,6% YoY
• ▍Net margin -381.7%

Revenue $828.0k; Operating income -$12.5M.

• ▍Revenue $828.0k
• ▍Operating income -$12.5M
• ▍Net margin -3249.8%

Revenue $1.2M; Operating income -$16.4M.

• ▍Revenue $1.2M
• ▍Operating income -$16.4M
• ▍Net margin -964.2%

Revenue $1.2M; Operating income -$12.1M.

• ▍Revenue $1.2M
• ▍Operating income -$12.1M
• ▍Net margin -1055.5%

Revenue $976.0k; Operating income -$11.7M.

• ▍Revenue $976.0k
• ▍Operating income -$11.7M
• ▍Net margin -1127.6%

Revenue $4.7M, +8,3% YoY; Operating income +1,0% YoY.

• ▍Revenue $4.7M, +8,3% YoY
• ▍Operating income +1,0% YoY
• ▍Net income −27,4% YoY
• ▍Free cash flow −33,1% YoY
• ▍Net margin -1232.7%

Revenue $4.3M, +79,0% YoY; Operating income −5,6% YoY.

• ▍Revenue $4.3M, +79,0% YoY
• ▍Operating income −5,6% YoY
• ▍Net income +13,6% YoY
• ▍Free cash flow −4,2% YoY
• ▍Net margin -1047.6%

Revenue $2.4M, +544,0% YoY; Operating income +13,6% YoY.

• ▍Revenue $2.4M, +544,0% YoY
• ▍Operating income +13,6% YoY
• ▍Net income +6,2% YoY
• ▍Free cash flow +8,6% YoY
• ▍Net margin -2169.1%

Revenue $377.0k, −24,6% YoY; Operating income −104,9% YoY.

• ▍Revenue $377.0k, −24,6% YoY
• ▍Operating income −104,9% YoY
• ▍Net income −100,0% YoY
• ▍Free cash flow −90,6% YoY
• ▍Net margin -14899.5%